← Patent-cliff monitor Loss of exclusivity March 2030 latest FDA-listed patent expiry
Company AbbVie Inc. → See this company's full patent-cliff portfolio Drug detail Brand name VRAYLAR Active ingredient CARIPRAZINE HYDROCHLORIDE Strength EQ 4.5MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval September 2015 Marketing status RX
Listed patents Patent Expires Type 7737142*PED March 2030 — RE49110*PED January 2030 — RE49302*PED January 2030 — 7737142 September 2029 substance, product RE49110 July 2029 use U-2545 RE49302 July 2029 use U-2545 7943621*PED June 2029 — 7943621 December 2028 substance, product
Regulatory exclusivity Code Expires PED June 2029 M-14 December 2028 NPP December 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.